Zoetis Inc. (NYSE:ZTS) Stock Has Consensus Price Target of $98.07

Shares of Zoetis Inc. (NYSE:ZTS) have received an average recommendation of “Hold” from the nineteen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $93.79.

Several analysts have recently weighed in on ZTS shares. HSBC lowered their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Jefferies Financial Group cut Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $103.00 to $83.00 in a report on Tuesday, October 20th. UBS Group boosted their target price on Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday. Finally, The Goldman Sachs Group began coverage on Zoetis in a research note on Friday, October 16th. They set a “neutral” rating and a $74.00 price objective on the stock.

Institutional Trading of Zoetis

Institutional investors have recently made changes to their positions in the stock. Ascent Group LLC lifted its position in Zoetis by 31.7% during the 3rd quarter. Ascent Group LLC now owns 14,310 shares of the company’s stock valued at $999,000 after acquiring an additional 3,444 shares during the period. Kelleher Financial Advisors boosted its stake in shares of Zoetis by 239.2% during the 3rd quarter. Kelleher Financial Advisors now owns 563 shares of the company’s stock worth $39,000 after acquiring an additional 397 shares during the last quarter. Markel Group Inc. increased its holdings in Zoetis by 542.5% in the 3rd quarter. Markel Group Inc. now owns 425,296 shares of the company’s stock worth $29,698,000 after acquiring an additional 359,101 shares in the last quarter. Parr Mcknight Wealth Management Group LLC boosted its stake in shares of Zoetis by 9.2% in the third quarter. Parr Mcknight Wealth Management Group LLC now owns 21,501 shares of the company’s stock worth $1,501,000 after acquiring an additional 1,811 shares during the period. Finally, Provenance Wealth Advisors LLC raised its position in shares of Zoetis by 1,866.7% during the third quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company’s stock valued at $37,000 after buying an additional 504 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Stock Performance

NYSE ZTS opened at $79.67 on Monday. The stock has a market capitalization of $32.92 billion, a PE ratio of 11.98, a P/E/G ratio of 1.17 and a beta of 0.74. Zoetis has a 1 year low of $68.77 and a 1 year high of $144.83. The company’s 50 day simple moving average is $75.04 and its two-hundred day simple moving average is $93.64. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the business posted $1.76 earnings per share. The firm’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis will post 6.15 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.